Skip to main content


20.02.2020 Press releases

MedImpact receives three-year NCQA reaccreditation.

Commitment to high quality standards and rigorous process assessment results in 100% score

SAN DIEGO, CA (06/03/2019) — MedImpact, the independent pharmacy benefit manager (PBM) that puts clients and consumers first, announced today that it has been awarded a three-year reaccreditation in utilization management by the National Committee for Quality Assurance (NCQA).

Most notably, MedImpact achieved a 100% score across multiple quality standards, following a rigorous assessment of its processes for vital healthcare management services. Because of the exceptionally high-score, MedImpact received a three-year accreditation versus the standard two-year accreditation.


“For 30 years, we have helped ensure members receive the services and prescriptions they need for better health, while preventing the risks and costs associated with over-utilizing resources. NCQA accreditation is the gold standard for quality in healthcare, and we are pleased to be recognized for our clinical excellence, unrelenting commitment to members, and track record of continuous improvement.”


As an independent nonprofit, NCQA works to improve the quality of healthcare and conducts voluntary, objective, and evidence-based evaluations. To be awarded the three-year accreditation, MedImpact underwent a rigorous assessment of its systems, processes, and personnel in utilization management to ensure NCQA’s high standards are met. NCQA accreditation is critical for PBM partnerships with health plans, managed care organizations, and accountable care organizations.

Since its inception, MedImpact has invested heavily in building a world-class clinical team, leading the way in innovation, and providing the highest touch member services. It is an approach that delivers forward-thinking utilization management, high-touch member engagement programs, and low year-over-year trend. Today, MedImpact is the largest independent PBM, serving many of the nation’s most recognizable health plans and self-insured employers, and 55 million consumers globally.

“While the industry may be distracted by mergers and acquisitions and other corporate issues, we will remain singularly focused on our clients and members,” said Watanabe. “We are proud to receive this accreditation, but we are even more excited about the innovation we will bring over the upcoming months to improve health, lower costs, and deliver a consumer experience that will redefine pharmacy benefits management.”

NCQA has reviewed and accredited MedImpact’s Utilization Management functions only. For complete details on the scope of this review, visit

About MedImpact

MedImpact is the PBM that puts clients and consumers first. For 30 years, it has had a single mission: To make pharmacy benefits affordable, understandable, and transparent. Today, MedImpact’s team and technology serve many large employers and plans, and more than 55 million consumers in the US and around the world. Learn more at or follow us on Twitter @MedImpact.

About NCQA

NCQA is a private, non-profit organization dedicated to improving healthcare quality. NCQA accredits and certifies a wide range of healthcare organizations. It also recognizes clinicians and practices in key areas of performance. NCQA’s website ( contains information to help consumers, employers and others make more informed healthcare choices.

Read on.
Keep up to date on the latest in the industry.
Client news
FDA approves first and only treatment for common mutation in advanced breast cancer.
The FDA approved a new drug that is a potential game changer for advanced breast cancer patients. Piqray (alpelisib) gained approval on May 24 for treatment of postmenopausal women and men with one of the most commonly mutated genes in advanced or metastatic breast cancer.
Client news
Can you put a price on life?
FDA approves world’s most expensive drug with broad indication to treat rare childhood neuromuscular disease.
Client news
Investigating top diabetes trends by lines of business.
Diabetes spending will continue to increase as new pipeline agents like oral semaglutide enter the market. For now, insulin still dominates the diabetes therapeutic class, accounting for 49% of market share. Newer generation, non-insulin products, like DPP4, SGLT2 or GLP-1s, or combinations that contain them, now make up a combined 50% of market share.

Ready for clarity from your PBM?